Oncolytics Biotech Inc T.ONC

Pelareorep + Paclitaxel = Metastatic HR+/HER2– Breast Cancer

[Noteable]

July 03, 2023 -  Pelareorep Plus Paclitaxel Induces Responses in Metastatic HR+/HER2– Breast Cancer

https://www.onclive.com/view/pelareorep-plus-paclitaxel-induces-responses-in-metastatic-hr-her2-breast-cancer

[Noteable]

De-escalation of axillary surgery performed to remove breast cancer that has already spread to nearby lymph nodes and prevent further metastasis could reduce the likelihood of a patient with breast cancer developing postoperative complications, including arm lymphedema, chronic pain, chronic fluid collections, problems with range of motion in the shoulder, and axillary web syndrome.

[Noteable]

Regarding safety, patients treated with pelareorep experienced fever, chills, and/or mild-like flu symptoms, which outside of this clinical trial setting could be treated with acetaminophen (Tylenol).

[Noteable]

Pharmacokinetic data showed that significant expansion of T-cell clones was observed by cycle 4 in patients treated with pelareorep plus paclitaxel, which supports the understanding that pelareorep is able to overcome an immunosuppressive tumor microenvironment (TME) and T-cell exhaustion, which is ultimately responsible for tumor escape ( Wang J, Xu Y, Huang Z, Lu X. T Cell exhaustion in

[Noteable]

" Two different ADCs, namely trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have already entered clinical practice for the treatment of HER2-positive ABC. In this scenario, T-DXd has shown to portend better survival outcomes compared to T-DM1, while leaving a large unsought area of unmet medical need upon T-DXd failure." https://www.esmoopen.com/article/S2059-7029(23

[Noteable]

May 15, 2024 - ESMO Breast Cancer 2024 - "At ESMO Breast Cancer 2024 (Berlin, 15–17 May), long-awaited results from the IMpassion132 trial revealed that adding atezolizumab to chemotherapy did not prolong survival versus placebo in PD-L1-positive patients with advanced triple-negative breast cancer (TNBC) relapsing within 12 months after anthracycline

[Noteable]

April 23, 2024 - Novartis investors are anxiously awaiting another label expansion for Kisqali in early-stage HR-positive, HER2-negative breast cancer, for which the company filed an FDA application in December.  [ Kisqali (Ribociclib) is used in combination with letrozole in patients with hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer. It is also